本刊特点：CSCD核心期刊（2023-2024）,高质量科技期刊（T1）,SCIE（2024版）, 科技核心期刊（2024自然科学）,维普收录,万方收录,知网收录,第一批认定学术期刊,外文期刊,
期刊基本信息
出版周期：月刊 级别：核心期刊
主管部门：中国科学技术协会
主办单位：中国抗癌协会、天津医科大学肿瘤医院
编辑部：《癌症生物学与医学（英文版）》编辑部
中国国内刊号：CN12-1431/R
国际标准刊号：ISSN 2095-3941
邮发代号：6-173
价格：120元/期
知网复合影响因子：2.314
知网综合影响因子：1.724
杂志社联系方式
地址：天津市河西区体院北环湖西路天津市肿瘤医院C座综合楼三楼
邮编：300060
电话：022-23522919
传真：022-23522919
杂志邮箱：editor@cancerbiomed.org
官方网站：http://www.cancerbiomed.org/
杂志征稿投稿要求
《癌症生物学与医学（英文）》投稿须知
【官网信息】
Instructions for Authors
ABOUT THE JOURNAL
Cancer Biology & Medicine is a peer-reviewed open-access journal sponsored by the China Anti-cancer Association (CACA), which is the leading professional society of oncology in China, and Tianjin Medical University Cancer Institute and Hospital (TMUCIH). Published quarterly, the journal provides innovative and significant information on biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China. The journal adheres to the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, issued by the International Committee for Medical Journal Editors (ICMJE) and the guidelines of Committee on Publication Ethics (COPE).
Aims and Scope
Cancer Biology & Medicine is dedicated to reporting latest advances in cancer research around the world by presenting high quality articles, especially on translational cancer research, to bridge the gap between basic and clinical cancer research. Meanwhile, the journal promotes academic exchange in cancer area between China and the rest of the world to keep cancer researchers and clinicians updated with current knowledge of novel findings and recent advances in oncology. The scope covers the following topics:
● Cancer genetics
● Cancer and stem cell biology
● Molecular and clinical immunology
● Cancer prevention and epidemiology
● Cancer biomarkers
● Radiation oncology
● Oncology clinical trials
● Mechanisms of drug sensitivity and resistance
● Targeted therapy and immunotherapy
● Multidisciplinary treatment and personalized medicine
AUDIENCE
Cancer Biology & Medicine endeavors to appeal a diverse audience engaged in cancer research and subspecialties in clinical oncology. Readers may include, but not limited to, investigators, physicians, surgeons and nurses in cancer research areas, medical students, and other relevant health care professionals.
CONTENT CATEGORIES
Original Article, Editorial, Perspective, Review, Minireview, Letter to the Editor, Practice Guideline, and MDT Case Study.
INDEXING INFORMATION
Cancer Biology & Medicine is indexed in SCIE, PubMed/PubMed Central, BIOSIS Previews, EMBASE, SCOPUS, EBSCO, DOAJ, and Chemical Abstracts.
EDITORIAL POLICIES
Authorship and Contributorship
Authorship credit should be based on 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. The manuscript’s content and its submission for publication should be approved by all authors who should sign off in the author form prior to submission. Revisions and final version should be approved by all authors. Contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section.
Except for ensuring that authors are appropriately listed and providing information on the specific contributions each author has made to the article, the corresponding author is also required to offer the Open Researcher and Contributor Identifier (ORCID) ID before proceeding with submission. He/she could register an account of ORCID via this link: https://orcid.org/. By the way, please be aware that all communication during the submission and publishing process will be sent to the corresponding author. Co-first authors and co-corresponding authors are acceptable, but no more than 2. In cases with co-corresponding authors, a primary one must be designated as the point of contact responsible for all communication and will be listed firstly.
Ethics Involving Humans and Animals
The welfare of animals used for research must be respected. Animal experiments should abide by the institutional and national guide for the care and use of laboratory animals. For primary research manuscripts in Cancer Biology & Medicine reporting experiments on animals, the authors must confirm that all experiments were performed in accordance with relevant guidelines and regulations. Manuscripts must include a statement in materials and methods section that the research has been reviewed and approved by institutional ethical committee before conduction.
Experiments on human subjects should follow the Helsinki Declaration (as revised in 2013) and should be approved by an ethics committee. Concerning privacy and/or security of personal information, informed consents and permissions must be obtained in regard to case details, personal information, and/or images used. When reporting studies that involve human participants, authors should include a statement that the studies have been approved by the appropriate institutional and/or national research ethics committee and have been conducted in accordance with Declaration of Helsinki. For manuscripts reporting biomedical research involving human subjects, a statement that the informed consent was obtained from each subject is required. If the study is a clinical trial, the trial must be registered in an appropriate registry prior to the start of the trial. Authors should provide ClinicalTrials.gov Identifier in the manuscript.
For all research involving human subjects, informed consent should be obtained from participants or their legal guardian and a statement to this effect should appear in the manuscript. Informed consent must comply with all applicable laws and regulations concerning the privacy and/or security of personal information. Patients' names, initials, social security numbers, dates of birth or other personal or identifying information should not be used. Images of patients should not be used unless the information is essential for scientific purposes and explicit permission has been given as part of the consent. Identifying details should be omitted if they are not essential.
Conflict of Interest
Conflict of interest exists when an author (or the author’s institution), reviewer, or editor has any financial or personal relationships that may inappropriately influence (bias) his or her actions. Cancer Biology & Medicine requires all authors to disclose any relationship that might result in an actual, potential, or perceived conflict of interest about the manuscript submitted for review. Reviewers and editors should also disclose all relationships that may undermine the credibility of the publication process. Conflict of Interest Statement should be written as a section before References.
Exclusive Submission
Manuscripts are considered for review only if no part of the work has been previously published in print or electronically. Previous publication of an abstract in the proceedings of meetings does not preclude whole manuscript submission for publication, but full disclosure should be made. At submission, the corresponding author is responsible to attest that the manuscript, in whole or in part, is not under consideration, in press, or published in any other publication or electronic medium.
Copyright and Permissions
If a manuscript includes copyrighted materials of others, authors must obtain written permission from the copyright owners and indicate the sources in the article. The written permission should be simultaneously submitted with the manuscript.
Checking for Scientific Misconduct
Cancer Biology & Medicine has an obligation to ensure that its published articles are accurate and adheres to the highest ethical standard. Editors check all submissions using CrossCheck. In the cases of plagiarism, redundant or duplicate publication, the journal will send a letter of reprimand to the authors’ institution, publish a notice of misconduct and formally retract the published manuscript. The journal will remove further association with the involved authors and institutions.
Peer Review
After initial review by the editor or sometimes by an editorial board member, manuscripts without sufficient priority for publication will be editorially rejected within 7 days. Those qualifying for peer review will be sent to at least two expert reviewers for unbiased, independent and critical assessment. Reviewers are asked to provide an overall recommendation supported by detailed comments on the quality and originality of the science as well as the applicability and impact of the reported results and conclusions. In addition, the scientific validity of statistical analysis and data of clinical trial articles will be evaluated by reviewers. Peer reviewers’ identities are kept confidential, but authors’ information will be provided to the reviewers. The editors endeavor to reach decisions on these papers within four weeks from the original submission date. We allow authors two weeks for general revision and one month for major revision. Accepted papers will be published in print within four months of acceptance.
Embargo Policy
Scientific information in a manuscript which is under consideration or in press in Cancer Biology & Medicine may not be discussed with the media before publication. Preliminary reporting to public media, governmental agencies, or manufacturers should not jeopardize publication, and should be discussed with and approved by the editor in advance.
Corrections and Retractions
Corrections to articles after online publication will only be made for errors that compromise the scientific record, such as a mistake in an author’s name, or that substantially impact the meaning or interpretation of the data but that do not compromise the overall results or conclusions of the article. A correction should be published as soon as reasonably possible.
Retractions refer to an article in its entirety that is the result of a pervasive error, nonreproducible research, scientific misconduct, or duplicate publication. In instances of retraction due to misconduct, the corresponding author’s institute and funding agency will be notified, according to COPE guidelines (https://publicationethics.org/guidance/Guidelines).
Editors may consider issuing an Editorial Expression of Concern if they have well-founded concerns and feel that readers should be made aware of potentially misleading information contained in an article. Scenarios in which Editorial Expressions of Concern may be published include prolonged investigations of very complex cases and when the concerns may have a significant and immediate impact on public health or public policy. An Editorial Expression of Concern may be superseded by a subsequent Correction or Retraction, but will remain part of the permanent published record.
Advance Online Publication
All accepted articles will be published online (www.cancerbiomed.org) before print as the final version after revision and editing, with a unique digital object identifier (DOI).
Open Access
All accepted articles will be archived as open access documents at www.cancerbiomed.org and www.ncbi.nlm.nih.gov/pmc/journals/2000/.
Data Sharing
In order to maintain the integrity, transparency and reproducibility of research records, authors must make their research data openly available either by depositing into data repositories or by publishing the data and files as supplementary information in the journal. The journal encourages and enables authors to share data that supports their research publication where appropriate. To facilitate reproducibility and data reuse, we also encourages authors to share their software, models, algorithms, protocols, methods and other useful materials related to the research.
MANUSCRIPT SUBMISSION
Presubmission Inquiries
Authors interested in getting rapid feedback on whether a manuscript is likely to be published in Cancer Biology & Medicine are encouraged to send inquiries by e-mail (editor@cancerbiomed.org). The inquiries should at least include an abstract and significant figures and tables. A paper that is invited for submission after a presubmission inquiry is still subject to editorial review to assess for external peer review.
Online Submission
We encourage authors to submit manuscripts via our online submission and tracking system: http://mc03.manuscriptcentral.com/cbm. Please avoid sending your manuscript by e-mail attachment.
Questions and required documents in submission process:
● Manuscript type
● Manuscript title
● Running title with no more than 10 words
● Full names including first and middle names of all authorsshould be provided, the affiliation of everyone, as well as thee-mail address of corresponding author(s) should be also included
● Abstract is the sketch of core content of the whole paper,particularly, it should offer the purpose of the study, themethods used, and results and conclusions in an original article.References could not appear in abstract, also, abbreviations andacronyms should be avoided
● At least 5 keywords should be provided on the maininformation of the paper
● A cover letter should be uploaded along with the paper (seemore details below)
● The approval from an ethics committee should be offered whenthe paper, especially original article, refers to clinical trials
● Upload PDFs or other files for Supplementary Data (if applicable)
● Answers to some other questions such as listing the reviewers recommended by author(s) and so on.
Our online submission system will prompt you to upload the components of your manuscript (cover letter, text, figures, supplemental data, etc.) as separate files. Upon completion of this step, the website will build a composite PDF file of your entire manuscript. Authors are responsible to check the format of manuscript and quality of figures in the converted PDF file and approve the submission.
Cover Letter
Each submission must be accompanied by a cover letter, which should contain the following information:
The title and a brief summary of the significant findings or points of the manuscript.
A statement of exclusive submission and no plagiarism or other misconducts.
A statement that the manuscript has been read and approved for submission by all the authors.
The name, address, and telephone number of the corresponding author.
Suggestions for appropriate reviewers and reviewer exclusions.
Status Inquiries
Authors can check the status of the submitted manuscripts at any time in the review process by accessing the system with their account and password. Please feel free to send status queries to the editor@cancerbiomed.org.
Revision Submission
The revised version of manuscript should be submitted within two months after authors receive the reviewers comments. Please contact the editor if extra time is needed for revision. The journal generally allows only one round of revision. Except for the revisions, authors should upload a point-by-point response to the reviewers’ comments. Please do not upload revised manuscripts as new submissions.
MANUSCRIPT FORMATS
Original Article
Original Articles report significant new findings or important clinical experience in cancer area, which have valuable implications.
● 300-word abstract
● 6,000 words of text
● 50 references or more
● 8 figures and/or tables in maximum
● Results and Discussion must not be combined.
● Additional display items may be published as supplementary information.
Editorial
Editorials are usually invited, commenting on the leading-edge discoveries in cancer research and significant advances on cancer diagnosis and treatment.
● 3,000 words of text
● 10 references or more
● 3 figures and/or tables in maximum
Perspective
Perspectives present a viewpoint on an important area of research and are written only at the invitation of the Editorial Board. Perspectives focus on a specific field or subfield within a larger discipline and discuss current advances and future directions, sometimes with personal insights.
● 3,500 words of text
● 10 references or more
● 3 figures and/or tables in maximum
Review
Reviews discuss recent progress on topics of broad interest to cancer researchers or cancer care professionals. Solicited reviews will also be sent out for peer review.
● 250-word abstract
● 7,000 words of text
● 75 references or more
● 7 figures and/or tables in maximum
Minireview
Minireviews are shorter reviews, usually based on recently published original studies. Solicited minireviews will also be sent out for peer review.
● 200-word abstract
● 4,000 words of text
● 50 references or more
● 5 figures and/or tables in maximum
Letter to the Editor
Readers are encouraged to comment on articles published in Cancer Biology & Medicine, via Letters to the Editor. Letters to the editor will not undergo peer review.
● A Letter should clearly indicate the original source.
● Response to a Letter should reference the Letter in the first paragraphs and its title should include the Letter title.
● 500 words of text
● 5 references or more
Practice Guideline
Practice Guidelines introduce consensuses or clinical guidelines produced by international authoritative groups or societies about cancer.
Multi-disciplinary Team (MDT) Case Study
MDT case study integrates theragnostic analysis on representative patient case from multi-disciplinary experiences which provides practical information for clinicians.
● 200-word abstract
● 3,000 words of text
● 30 references or more
● 5 figures and/or tables in maximum
MANUSCRIPT PREPARATION
Authors should prepare their manuscripts according to the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals established by the ICMJE (http://www.icmje.org) (http://www.icmje.org). The editors have the right to return manuscripts that are not in accordance with the journal’s policies and format requirements. Manuscripts must be written in concise and fluent English. It is suggested that authors have their manuscript reviewed by colleagues and/or by professional English language editing services before submission.
The manuscript of observational and experimental articles should include title page, abstract, introduction, materials and methods, results, discussion, acknowledgements, conflict of interest statement, references, figures, tables, and supplementary information. All pages of the manuscript should be numbered consecutively, beginning with the title page.
Title Page
Title Key information should be included in the title, which enables electronic retrieval of the article both sensitive and specific. The title should not contain any abbreviations except for commonly used gene or protein acronyms. The total length of the title should not exceed 20 words.
Authors and Affiliations For each author, the name, mailing address, telephone and fax numbers, and e-mail address should be indicated clearly; numbers in superscript should be used to indicate the department, institution, city with postal code and country.
Author Contribution Cancer Biology & Medicine requires a statement specifying the contributions of every author on the title page.
Source(s) of Support Any support in the form of grants, equipment, drugs, or all of these should be claimed.
Running Title A running title of no more than 10 words is required.
Abstract
This should be a single paragraph of about 250 words, accurately reflecting the content of the article. Abbreviations and reference citation should be avoided in the abstract. The abstract should describe all key novel findings of the study. Structured abstracts (Objective, Methods, Results, and Conclusion) are preferred for original research articles. For articles on clinical trials, items identified by the CONSORT group should be provided and the trial registration number should be listed at the end of the abstract.
Keywords
Authors should list keywords (up to five) which reflect the key information of the article. Medical Subject Headings (MeSH) should be used as a guide (http://www.nlm.nih.gov/mesh/meshhome.html).
Introduction
The Introduction section should provide the necessary background and the specific purpose of the research. Cite references to the most pertinent articles and avoid including data or conclusion of the study being reported.
Materials and Methods
Information about materials and methods should be brief and adequate so that all procedures can be repeated by others. Methods that have been well described in previous publications should be merely cited with appropriate references. Only new and substantially modified methods need detailed explanation. The generic name (s), dose (s), and administration route (s) of all drugs and chemicals should be precisely identified.
Describe statistical methods with enough details. Provide references for the statistical methods when possible and explain whether their data conform to the assumptions of the tests. The computer software used should be specified. Authors should be aware that statistical analysis and presentation is an essential part to review for all referees.
Manuscripts involving humans and animals must include a statement in this section that the research has been reviewed and approved by institutional ethical committee before conduction of research. For manuscripts involving human subjects, a statement that the informed consent was obtained from each subject is required.
Results
The results should be presented in logical sequence in the text, tables, and figures, accurately describing important findings of the study. Concisely summarize the data presented in tables and figures, avoiding excessive explanations.
Discussion
Accurately interpret the new and important findings of the study and discuss the results in a broader context. Avoid repeating materials already showed in the Introduction or the Results section. Pertinent data in previous publications should be appropriately discussed and cited. Discuss the limitations and implications of the study. Avoid drawing conclusions without adequate support by the data.
Conflict of Interest Statement
In this section, whether there is a Conflict of Interest should be stated. Authors must disclose the details of all conflicts if there are any.
Acknowledgements
Contributions of non-authors should be acknowledged. The corresponding author is responsible to obtain the written permission from those mentioned in this section. The funding sources (if any) should be listed, with grant name and number.
References
Cancer Biology & Medicine requires the citation of original research articles wherever appropriate. Number the references in the order of their first mention. References should include only articles that are published or in press. Avoid citing abstracts, personal communication, or retracted articles. Authors are responsible for the accuracy of references and should ensure that the pertinent literatures are appropriately cited and comprehensively discussed. Please use the following style for references:
Article in a Journal: Ulivi P, Delmonte A, Chiadini E, CalistriD, Papi M, Mariotti M, et al. Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: are there features to guide patient selection? Int J Mol Sci. 2014; 16: 747-57.
Article in a book: Gradishar W. Male breast cancer. In: Harris J, Lippman M, Morrow M, Osborne C, eds. Diseases of the breast. 2nd ed. Philadelphia: Lippincott Williams & Wilkins. 2000: 661-7.
An entire book: Bruce A. Chabner, Dan L. Longo. Cancer Chemotherapy and Biotherapy: Principles and Practice. Philadelphia: Lippincott Williams & Wilkins. 2006.
Online first articles: Gregg W. Stone, Akiko Maehara, Bernhard Witzenbichler, et al. Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction: The INFUSE-AMI Randomized Trial. JAMA. Published online first: March 25, 2012. DOI: 10.1001/jama.2012.421
Tables
Type tables on separate sheets and number them consecutively in Arabic numerals according to the order of their first mention in the text. Tables should be self-explanatory and include a brief descriptive title above. Column headings should be concise, with units of measurement in parentheses. Explain all abbreviations in footnotes and use the following symbols, in sequence: †, ‡, §, ¶, etc. *, **, ***, etc. should be reserved for P values.
Figures
The number of figures for each manuscript format should not exceed the limitation as above mentioned. Importantly, graphic models with essential annotations and interpretations, such as pathway illustrations, are needed when the content refers to mechanism, theory, or core research findings, especially in review or original article.
Figures should be labeled in consecutive Arabic numerals and presented in the order they are mentioned in the text. If reuse of a figure in previously publications is necessary, the author must provide the written permission from the copyright holder and indicate the original source in the legend.
The figures should be submitted as separate files, in TIF, EPS, JPEG, or GIF formats and should be sized at 127×173 mm (5×7 inches). High resolution is preferred. At least 300 dpi for color figures and 1,000 dpi for line figures are required. Photomicrographs should have internal scale markers. Symbols, arrows, or letters used in photomicrographs should contrast with the background.
Figure legends should be concise and comprehensive and be listed in a separate page. Ensure that legends and figures match up correctly. Indicate stains and magnifications and clearly explain symbols, arrows, abbreviations, and letters used in the legends.
Supplementary Information
Supplementary data should enhance, but not be essential to, a reader's understanding of the paper. Without them, the article also must be complete and clear. Supplementary data will also be sent out for peer review as equal in quality as the main paper.
Supplementary files may consist of the following contents:
● Figures and/or tables
● Materials and methods mentioned in the main paper should be described in details
● Database information
● Electronic multimedia documents (e.g., videos, audios)
Restrictions on number and size of files:
● The number of supplementary files per article should not exceed 8.
● The file size should not exceed 10 MB.
Submit supplementary information as a separate file through thesubmission system.
Each supplementary item/file must be referenced at least once in the paper. The form of tables or figures in supplementary items should follow the related requirements used for the manuscript, for instance, “Figure S1” stands for supplementary Figure 1, or“Table S3” stands for supplementary Table 3.
PROOFS
Authors whose articles are accepted will receive an e-mail with their proof before publication. Authors should check the accuracy and the layout of the text, tables and figures. The PDF should be clearly annotated for necessary corrections and then returned via e-mail to editor@cancerbiomed.org by the date indicated. Major alterations which may delay the publication are not encouraged.
CHARGES
As an open access journal, Cancer Biology & Medicine charges a reasonable publication fee of $1,500/¥10,000 for each accepted article (all article types).
No fees will be charged for invited articles.
OFFPRINTS
Offprint order forms will be sent with the proofs. Authors who request offprints should complete and return the forms to the editorial office before the journal is printed. Late orders submitted after the print publication may be subject to an increased price.
CONTACT INFORMATION
Tianjin Medical University Cancer Institute and Hospital,
Huan-hu-xi Road, He-xi District, Tianjin 300060, China
Tel: 8622-23522919
Fax: 8622-23522919
E-mail: editor@cancerbiomed.org
Website: www.cancerbiomed.org